---
{"dg-publish":true,"permalink":"/entities/research/pmid-32891636-berberine-ampk-meta-analysis/","tags":["berberine","AMPK","type 2 diabetes","meta-analysis","glucose metabolism","systematic review"]}
---


# Efficacy and safety of berberine for type 2 diabetes: A systematic review and meta-analysis

## Study Information
**Authors**: Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J
**Journal**: Frontiers in Pharmacology
**Publication Date**: 2020-09-01
**Type**: Meta-Analysis
**Study Design**: Systematic Review and Meta-Analysis
**Evidence Level**: 1a
**Citations**: 285
**DOI**: [10.3389/fphar.2020.01260](https://doi.org/10.3389/fphar.2020.01260)
**PMID**: [32891636](https://pubmed.ncbi.nlm.nih.gov/32891636/)
**PMC**: [PMC7453919](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453919/)
**Semantic Scholar**: [View](https://www.semanticscholar.org/paper/PMID:32891636)

## Abstract
This systematic review and meta-analysis of 46 randomized controlled trials (n=4,158 participants) evaluated the efficacy and safety of berberine for type 2 diabetes. Berberine significantly reduced fasting blood glucose, HbA1c, and improved lipid profiles through AMPK activation. The analysis demonstrated berberine's potential as an adjunct therapy for metabolic disorders.

## Keywords
berberine, AMPK, type 2 diabetes, meta-analysis, glycemic control, lipid metabolism, insulin sensitivity

## Relationships
STUDIES::[[entities/drug/Berberine\|Berberine]] - Primary intervention across 46 RCTs
ACTIVATES::[[entities/protein/AMPK\|AMPK]] - Primary mechanism of action (AMP-activated protein kinase)
TREATS::[[entities/condition/Diabetes\|Diabetes]] - Target condition (type 2 diabetes mellitus)
DECREASES::[[entities/labtest/glucose\|Glucose]] - Primary outcome (fasting blood glucose reduction)
IMPROVES::[[entities/condition/Insulin Resistance\|Insulin Resistance]] - Secondary metabolic outcome
AFFECTS::[[entities/Organ/Liver\|Liver]] - Hepatic glucose production reduction
AFFECTS::[[entities/Organ/Pancreas\|Pancreas]] - Beta cell function improvement
RELATED_TO::[[entities/condition/Metabolic Syndrome\|Metabolic Syndrome]] - Broader metabolic effects demonstrated
INVOLVES::[[entities/protein/PGC-1alpha\|PGC-1alpha]] - Downstream AMPK signaling target

## Methodology
```yaml
design: Systematic review and meta-analysis
databases_searched:
  - PubMed
  - Cochrane Library
  - EMBASE
  - CNKI
  - Wanfang
inclusion_criteria: RCTs comparing berberine with placebo or standard care in T2DM
quality_assessment: Cochrane Risk of Bias tool
statistical_method: Random-effects model (DerSimonian-Laird)
```

### Study Design
- **Sample Size**: n=4158
- **Duration**: 4-24 weeks (across included studies)
#### Population Characteristics
```yaml
total_studies: 46
participants: 4158
age_range: Adults with type 2 diabetes
health_status: Type 2 diabetes mellitus
```

## Results
### Key Findings
```yaml
primary:
  - name: Fasting blood glucose
    result: Significant reduction (MD: -0.87 mmol/L)
    p_value: <0.00001
    heterogeneity: I2 = 89%
  - name: HbA1c
    result: Significant reduction (MD: -0.72%)
    p_value: <0.00001
secondary:
  - name: Total cholesterol
    result: Significant reduction (MD: -0.58 mmol/L)
  - name: LDL cholesterol
    result: Significant reduction (MD: -0.38 mmol/L)
  - name: Triglycerides
    result: Significant reduction (MD: -0.41 mmol/L)
  - name: Adverse events
    result: Mild GI symptoms, similar to control
```

### Statistical Analysis
#### Statistical Significance
```yaml
fbg: p < 0.00001, MD: -0.87 mmol/L, 95% CI: -1.09 to -0.64
hba1c: p < 0.00001, MD: -0.72%, 95% CI: -0.91 to -0.54
```
#### Effect Sizes
```yaml
fbg_reduction: 0.87 mmol/L (15.7 mg/dL)
hba1c_reduction: 0.72%
nnt: Approximately 4-5 for clinically meaningful improvement
```

## Limitations
- High heterogeneity among studies (I2 = 89%)
- Variable berberine dosages (0.5-1.5 g/day)
- Mostly Chinese study populations
- Short to medium duration studies
- Potential publication bias

## Research Integrity
### Funding Sources
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
### Conflicts of Interest
- None declared

## Replication Status
Consistent with previous meta-analyses; findings support earlier systematic reviews

## References
- Yin J et al. Metabolism. 2008;57(5):712-717. PMID: 18442638
- Kong W et al. Nat Med. 2004;10(12):1344-1351. PMID: 15531889
- Zhang Y et al. J Clin Endocrinol Metab. 2008;93(7):2559-2565. PMID: 18397984

## Source Data
- **Source System:** PubMed
- **Last Modified in Source:** 2025-01-22